Thryv Therapeutics licences a new class of SGK1 inhibitors from Spanish researchers to target Parkinson's and Alzheimer's

Thryv Therapeutics, a clinical stage biotechnology firm originally focused on heart conditions, has secured an exclusive worldwide licence for an entirely new chemical series designed to block a cellular enzyme called SGK1. The breakthrough compounds come from academic researchers at the Spanish National Research Council and the Autonomous University of Madrid. While Thryv already develops SGK1 blocking drugs for cardiac rhythm and heart failure conditions, this agreement gives them a brand new chemical foundation purpose built to cross into the central nervous system, opening a direct therapeutic path toward Parkinson's, Alzheimer's, and related neurodegenerative disorders. To understand why this development matters, it helps to look inside the cell at what SGK1 actually does. The acronym stands for serum glucocorticoid inducible kinase 1. Kinases act like internal master switches, attaching chemical tags to other proteins to turn biological processes up or down. Under normal circumstances, SGK1 responds to stress hormones and helps cells manage survival signals. However, when SGK1 becomes overactive or chronically switched on in the brain, it sits at the crossroads of several damaging biological events. Scientific research has shown that overactive SGK1 promotes neuroinflammation, interferes with protective stress defence pathways managed by cellular sensors like NRF2 and FOXO, and disrupts how cells clear toxic, misfolded proteins. In Parkinson's, impaired protein clearance and cellular stress allow rogue proteins to clump together, which places heavy metabolic strain on dopamine producing nerve cells. In Alzheimer's, hyperactive SGK1 is implicated in the abnormal chemical modification of tau proteins, leading to harmful tangles. By turning down the activity of SGK1, scientists hope to relieve this multi front cellular distress, quiet neuroinflammation, and help brain cells survive. Until now, the main hurdle has been the chemistry. Thryv built its early pipeline around molecules tailored for the heart, including their lead compound THRV 1268, which is currently in mid to late stage clinical testing for genetic cardiac rhythm disorders. Heart drugs, however, rarely cross the blood brain barrier, which is the body's strict border control that protects the brain from foreign substances. Modifying a heart drug so that it can enter the brain is notoriously tricky and often weakens how well it works. The licensed discovery solves this problem by offering an entirely separate chemical blueprint, known in pharmacology as a scaffold. This distinct scaffold was designed from scratch by a multidisciplinary team of medicinal chemists and neurobiologists in Spain, including Dr Ana Martínez, Dr Carmen Gil, and Dr Isabel Lastres Becker. Because these compounds were engineered from the ground up to tackle neurological targets, the development team does not need to compromise existing heart molecules. Instead, they can pursue brain penetration directly. Under the agreement, which took effect in July 2026, Thryv holds worldwide rights to develop and commercialise this new class of SGK1 inhibitors across all medical uses. The company intends to run the neurological programme alongside its cardiac pipeline, beginning laboratory characterisation immediately. The team aims to nominate their first official clinical drug candidate from the series in 2027. While translating laboratory discoveries into clinical treatments takes time and rigorous testing, targeting SGK1 offers a genuinely fresh angle on protecting brain cells, moving beyond standard symptom management toward tackling the underlying biological stress that drives progressive conditions.